108 related articles for article (PubMed ID: 9796047)
1. Induction of HIV-1 IIIb neutralizing antibodies in BALB/c mice by a chimaeric peptide consisting of a T-helper cell epitope of Semliki Forest virus and a B-cell epitope of HIV.
Fernández IM; Golding H; Benaissa-Trouw BJ; de Vos NM; Harmsen M; Nottet HS; Golding B; Puijk WC; Meloen RH; Snippe H; Kraaijeveld CA
Vaccine; 1998 Dec; 16(20):1936-40. PubMed ID: 9796047
[TBL] [Abstract][Full Text] [Related]
2. Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines.
Fernández IM; Harmsen M; Benaissa-Trouw BJ; Stuij I; Puyk W; Meloen RH; Snippe H; Kraaijeveld CA
Vaccine; 1998 Oct; 16(16):1531-6. PubMed ID: 9711800
[TBL] [Abstract][Full Text] [Related]
3. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.
Fernández IM; Snijders A; Benaissa-Trouw BJ; Harmsen M; Snippe H; Kraaijeveld CA
J Virol; 1993 Oct; 67(10):5843-8. PubMed ID: 7690411
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O
J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490
[TBL] [Abstract][Full Text] [Related]
5. Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr.
Sarobe P; Lasarte JJ; Golvano JJ; Prieto I; Gullón A; Soto MJ; Labarga P; Prieto J; Borrás-Cuesta F
J Acquir Immune Defic Syndr (1988); 1994 Jul; 7(7):635-40. PubMed ID: 8207641
[TBL] [Abstract][Full Text] [Related]
6. A shared idiotope among antibodies against Semliki Forest virus.
Fernández IM; Ovaa W; Harmsen M; Benaissa-Trouw BJ; Bos NA; Kraaijeveld CA; Snippe H
Viral Immunol; 1994; 7(2):71-80. PubMed ID: 7531444
[TBL] [Abstract][Full Text] [Related]
7. A delayed-type hypersensitivity-inducing T-cell epitope of Semliki Forest virus mediates effective T-helper activity for antibody production.
Snijders A; Benaissa-Trouw BJ; Visser-Vernooy HJ; Fernandez I; Snippe H; Kraaijeveld CA
Immunology; 1992 Nov; 77(3):322-9. PubMed ID: 1282493
[TBL] [Abstract][Full Text] [Related]
8. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.
Palker TJ; Matthews TJ; Langlois A; Tanner ME; Martin ME; Scearce RM; Kim JE; Berzofsky JA; Bolognesi DP; Haynes BF
J Immunol; 1989 May; 142(10):3612-9. PubMed ID: 2469721
[TBL] [Abstract][Full Text] [Related]
9. A vaccine against Semliki Forest virus consisting of a monoclonal anti-idiotypic antibody cross-linked to a protein which contains virus-specific T-helper cell epitopes.
Kraaijeveld CA; Oosterlaken TA; Snijders A; Benaissa-Trouw BJ; Ekstijn GL; Snippe H
Antiviral Res; 1992 Oct; 19(4):275-84. PubMed ID: 1281391
[TBL] [Abstract][Full Text] [Related]
10. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and vaccine efficacy of synthetic peptides containing Semliki Forest virus B and T cell epitopes.
Snijders A; Benaissa-Trouw BJ; Snippe H; Kraaijeveld CA
J Gen Virol; 1992 Sep; 73 ( Pt 9)():2267-72. PubMed ID: 1383405
[TBL] [Abstract][Full Text] [Related]
12. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
13. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.
Laman JD; Schellekens MM; Lewis GK; Moore JP; Matthews TJ; Langedijk JP; Meloen RH; Boersma WJ; Claassen E
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):605-12. PubMed ID: 8369165
[TBL] [Abstract][Full Text] [Related]
14. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
[TBL] [Abstract][Full Text] [Related]
15. A combinatorial peptide library around variation of the human immunodeficiency virus (HIV-1) V3 domain leads to distinct T helper cell responses.
Estaquier J; Boutillon C; Georges B; Ameisen JC; Tartar A; Auriault C
J Pept Sci; 1996; 2(3):165-75. PubMed ID: 9231325
[TBL] [Abstract][Full Text] [Related]
16. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
17. A chemically defined synthetic vaccine model for HIV-1.
Nardelli B; Lu YA; Shiu DR; Delpierre-Defoort C; Profy AT; Tam JP
J Immunol; 1992 Feb; 148(3):914-20. PubMed ID: 1370524
[TBL] [Abstract][Full Text] [Related]
18. Antigenicity of HIV-derived T helper determinants in the context of carrier recombinant proteins: effect on T helper cell repertoire selection.
Manca F; De Berardinis P; Fenoglio D; Ombra MN; Li Pira G; Saverino D; Autiero M; Lozzi L; Bracci L; Guardiola J
Eur J Immunol; 1996 Oct; 26(10):2461-9. PubMed ID: 8898961
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus.
McLain L; Durrani Z; Wisniewski LA; Porta C; Lomonossoff GP; Dimmock NJ
Vaccine; 1996 Jun; 14(8):799-810. PubMed ID: 8817828
[TBL] [Abstract][Full Text] [Related]
20. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
